Directorio

We are doing this study to find out if the combination of two drugs called nanatinostat and valganciclovir (the study drugs) are a safe and effective option for treating lymphoma in people who are EBV-positive. We will use different doses of the study drugs to determine what dose appears to be ideal for most people. The safety and effectiveness of nanatinostat on its own will also be tested in a small number of study participants.

We are doing this study to find out if an experimental drug called STM-416 (the study drug) is a safe and effective option for patients with a history of high grade, non-muscle invasive bladder cancer (cancer only within the bladder) whose disease has returned and who require an operation to remove cancer from the bladder.

We are doing this study to find out whether hepatic artery infusion (HAI) pump therapy with floxuridine and dexamethasone is an effective treatment for cholangiocarcinoma that cannot be removed with surgery and has not been treated yet. We want to find out whether the HAI pump treatment plus GemOx chemotherapy works as well as or better than GemOx alone at extending the time before your disease gets worse.

We are doing this study to find the most effective, safe dose of an experimental drug called disitamab vedotin (the study drug). We want to know how well this study drug works in people who have advanced or metastatic solid tumors.

We are doing this study to find out if the study drug, patritumab deruxtecan, can be measured in brain tumor tissue after a single dose is given before surgery to remove brain metastases.

We are doing this study to compare the standard treatments (FOLFOX or CAPOX after chemoradiation) for rectal cancer to a drug regimen called FOLFIRINOX that is given after chemoradiation. We want to know if FOLFIRINOX after chemoradiation can provide better outcomes than either of the 2 standard treatments.

We are doing this study to find out if using Radium-223 dichloride (the study drug) in combination with cabozantinib is a safe and effective treatment for advanced RCC that has spread to the bone. We want to know if this combination is potentially better than the standard treatment of cabozantinib on its own.

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.